

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Genix Pharmaceutical Corp. (the “Company”)
Suite 804 – 750 West Pender Street
Vancouver BC V6C 2T7

Item 2: Date of Material Change

February 16, 2016.

Item 3: News Release

No news release was prepared for this material change as the Company is not a public company.

Item 4: Summary of Material Changes

The Company is pleased to announce the appointment of Paul Chow as a member of the board of directors of the Company effective immediately.

Item 5: Full Description of Material Change

The Company is pleased to announce the appointment of Paul Chow as a member of the board of directors of the Company effective immediately, following the resignation of Stephen Brohman as a director of the Company. The Company thanks Mr. Brohman for his role in management and wishes him the best in his future endeavors.

Mr. Chow has served as a founding partner, officer, director, and corporate consultant to several Canadian public and private businesses during his 15 year career in the capital markets. Mr. Chow has been involved in the strategic planning, marketing, and financing of companies from the start-up phase through to the initial public offering.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

For further information, please contact:

Christopher P. Cherry, CFO
604.682.2928

Item 9: Date of Report

February 17, 2016.